TrialBritish journal of cancer2015

A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results.

T Eisen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.